Interesting IMO that nobody have paid attention (as far as I know) to the control-placebo group in Polack et al. NEJM Dec 2020. That was the key paper for the anti SARS CoV2 RNAvax approval and their massive use in humans that followed. Only 9 ( yes, 9!!!!) cases of "serious symptoms" of COVID-19 among the 20.000 individuals in the place…
Interesting IMO that nobody have paid attention (as far as I know) to the control-placebo group in Polack et al. NEJM Dec 2020. That was the key paper for the anti SARS CoV2 RNAvax approval and their massive use in humans that followed. Only 9 ( yes, 9!!!!) cases of "serious symptoms" of COVID-19 among the 20.000 individuals in the placebo group, individuals collected in different countries (Brazil, Argentina, India, etc) at the peak of the pandemic in 2020. An approx. 150 positive cases (this is by lab detection, either mild or non symptomatic ) in the placebo group of 20.000 total. From this numbers they got the wildly propagandized number of "95%"of efficiency (1 and 15 positives, respectively, among the test group that received the RNAvax). No decent journal would have accepted publishing those RNA vax efficacy numbers against COVID-19 or any other viral disease, in under normal circumstances.
Interesting IMO that nobody have paid attention (as far as I know) to the control-placebo group in Polack et al. NEJM Dec 2020. That was the key paper for the anti SARS CoV2 RNAvax approval and their massive use in humans that followed. Only 9 ( yes, 9!!!!) cases of "serious symptoms" of COVID-19 among the 20.000 individuals in the placebo group, individuals collected in different countries (Brazil, Argentina, India, etc) at the peak of the pandemic in 2020. An approx. 150 positive cases (this is by lab detection, either mild or non symptomatic ) in the placebo group of 20.000 total. From this numbers they got the wildly propagandized number of "95%"of efficiency (1 and 15 positives, respectively, among the test group that received the RNAvax). No decent journal would have accepted publishing those RNA vax efficacy numbers against COVID-19 or any other viral disease, in under normal circumstances.